Natco Pharma Ltd

Natco Pharma FY26 Results: Key Financial Updates & Strategic Moves 📊

- Consolidated FY26 revenue: ₹40,783M (previous year: ₹44,295M)

- Consolidated FY26 net profit: ₹14,185M (previous year: ₹18,834M)

- Standalone FY26 revenue: ₹35,946M (previous year: ₹40,945M)

- Standalone FY26 net profit: ₹12,815M (previous year: ₹18,504M)

- Interim dividend of ₹1.5/share (total FY26 dividend: ₹5/share)

- Acquired 35.75% stake in Adcock Ingram Holdings Limited (₹19,912M deal)

- Approved demerger of Agro Chemical business to NATCO Crop Health Sciences Limited

- Recognized ₹500M impairment loss on Agro Chemical assets (FY25)

- Deferred tax asset of ₹1,150M due to tax option (effective FY27)